AI-generated summary
The authors report testing an RGD peptide and photobiomodulation, alone and combined, on scaffold-free bone-like microtissues made from human bone marrow stem cells and endothelial cells. Combined treatment was reported to induce osteogenic differentiation more than single treatments, with the 655 nm group showing the strongest effect. These are laboratory cell findings, not patient outcomes.
- Who or what was studied
- In vitro co-culture of human bone marrow stem cells and human umbilical vein endothelial cells formed into scaffold-free microtissues
- Wavelengths
- 655, 808 nm
- Limits stated in the abstract
- The abstract describes only cell culture experiments, so no clinical or patient outcomes are reported.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 600-800 nm, 655 nm, 808 nm
- Energy density (fluence)
- 1 J/cm2, 5 J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Reactive oxygen species, Wavelength, Adenosine triphosphate, Nitric oxide. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.